Genetically Engineered Mice as Experimental Tools to Dissect the Critical Events in Breast Cancer-Reference-Cited by-同舟云学术

Genetically Engineered Mice as Experimental Tools to Dissect the Critical Events in Breast Cancer

Published:2014 Issue: Volume: Page:331-382
ISSN:0065-230X
Container-title:Advances in Cancer Research
language:
Short-container-title:

Author:

Menezes Mitchell E.,Das Swadesh K.,Emdad Luni,Windle Jolene J.,Wang Xiang-Yang,Sarkar Devanand,Fisher Paul B.

Publisher

Elsevier

Reference165 articles.

1. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer;Abrams;Molecular Cancer Therapeutics,2003

2. GFP expression in the mammary gland for imaging of mammary tumor cells in transgenic mice;Ahmed;Cancer Research,2002

3. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation;Ahuja;Oncogene,2005

4. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis;Amundadottir;Cell Growth & Differentiation: The molecular biology journal of the American Association for Cancer Research,1995

5. Cooperation of TGF alpha and c-Myc in mouse mammary tumorigenesis: Coordinated stimulation of growth and suppression of apoptosis;Amundadottir;Oncogene,1996

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genes ingenuity pathway analysis unveils smoothelin‐like 1 (SMTNL1) as a key regulatory protein involved in sodium pentobarbital‐induced growth inhibition in breast cancer;Pharmacology Research & Perspectives;2023-11-09

2. Characterization of Mammary Tumors Arising from MMTV-PyVT Transgenic Mice;Current Issues in Molecular Biology;2023-05-24

3. Epidermal growth factor receptor targeted doxorubicin and vitexin loaded niosomes for enhanced breast cancer therapy;Materials Advances;2023

4. Bioassay-Guided extraction of andrographis paniculata for intervention of in-vitro prostate cancer progression in metabolic syndrome environment;DARU Journal of Pharmaceutical Sciences;2022-08-03

5. Conversion of a Non-Cancer-Selective Promoter into a Cancer-Selective Promoter;Cancers;2022-03-15